Leiden, Netherlands

Tian Shu Fan

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Stichting Vu. Active years: 2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tian Shu Fan. Retrieved from https://idiyas.com/inventor/tian-shu-fan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Tian Shu Fan in Antibody Development

Introduction

Tian Shu Fan is a notable inventor based in Leiden, Netherlands. He has made significant contributions to the field of biotechnology, particularly in the development of novel antibodies. His work focuses on therapeutic applications that can potentially improve patient outcomes in serious medical conditions.

Latest Patents

One of Tian Shu Fan's key patents is titled "Inverse agonistic anti-US28 antibodies." This invention relates to a novel class of antagonistic and inverse agonistic anti-US28 antibodies, specifically single heavy chain variable domain antibodies (VHH) and their variants and modifications. The patent also covers methods for producing these antibodies and their use in diagnostic and therapeutic applications, particularly for treating individuals suffering from CMV-positive tumors such as glioblastoma.

Career Highlights

Tian Shu Fan is associated with Stichting Vu, where he continues to advance his research and development efforts. His innovative approach to antibody design has the potential to lead to groundbreaking treatments in oncology and other fields.

Collaborations

Tian Shu Fan collaborates with talented individuals such as Martine Joyce Smit and Raimond Heukers, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Tian Shu Fan's work in developing inverse agonistic anti-US28 antibodies represents a significant advancement in therapeutic antibody research. His contributions are poised to make a meaningful impact on the treatment of serious medical conditions, particularly glioblastoma.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…